Macular Edema clinical trials at UCSF

1 research study open to eligible people

Macular edema is swelling of the macula, the part of the eye that gives sharp central vision. UCSF is testing a new medicine alone and with two commonly used eye drugs. The study measures safety, how the body handles the drug, and whether vision improves.

Showing trials for

  • RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

    open to eligible people ages 18 years and up

    This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.

    San Francisco, California and other locations

Last updated: